Skip to main content
70°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative
(NQ:
XOMAO
)
25.49
+0.14 (+0.55%)
Streaming Delayed Price
Updated: 11:00 AM EDT, Jul 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative
< Previous
1
2
Next >
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
June 27, 2025
From
XOMA Royalty Corporation; Turnstone Biologics Corp.
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
June 18, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
May 27, 2025
From
XOMA Royalty Corporation; BioInvent
Via
GlobeNewswire
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
May 13, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
May 07, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
April 14, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
April 02, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
March 20, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
March 17, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty to Present at Investor Conferences in March
February 24, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
December 19, 2024
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
December 02, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
November 07, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
October 22, 2024
From
XOMA Corporation
Via
GlobeNewswire
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
September 23, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
September 23, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty to Present at Upcoming Investor Conferences in September
September 04, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
August 13, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
June 12, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
May 14, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
April 30, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Corporation Announces Closing of Tender Offer
April 03, 2024
Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio
From
XOMA Corporation
Via
GlobeNewswire
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 08, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024
From
XOMA Corporation
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
